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Summary
Western lifestyle is associated with a sustained low grade increase in inflammation lead-
ing to an impaired innate immunity and reduced resistance to disease, changes which
might explain the epidemic of chronic diseases spreading around the globe. The immune
system cannot function properly without access to bacteria and plants, which when raw,
are rich not only in bacteria but also in plant fibres, antioxidants, healthy fats and numero-
us other nutrients. Modern food technology with plant breeding, separation, condensation
of food ingredients, heating, freezing, drying, irradiation, microwaving, an effective tool
for destroying foods and hereby counteracting optimal immune function, is suspected to
be a leading cause of so-called Western diseases. The supply of pre-, pro-, and synbiotics
has sometimes proved to be effective tool to counteract, especially acute diseases, but has
often failed, especially in chronic diseases. Thousands of factors contribute to unhealthy li-
ving. Numerous alterations in lifestyle and food habits are needed, if to prevent and cure
'treatment-resistant' chronic diseases. Among these are avoiding such processed foods that
are known to be rich in pro-inflammatory molecules, and also eating substantial amounts
of foods with documented anti-inflammatory effects such as turmeric/curcumin, molecu-
les which might be included in future synbiotic compositions.
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Western Food – A Threat to Human Health
Human life without access to plants and bacteria
would be miserable. Plants and bacteria, which have
existed for billions of years, often have robust protection
systems, which can be used by humans. Our Palaeo-
lithic forefathers did on annual basis receive their daily
food from at least five hundred plants and also, as the
food they ate was often stored in the soil, a rich supply
of various microorganisms. Modern food is based on nu-
trients received from only a small number of plants; 80
% of the nutrients come from 17 plants and 50 % of the
calories from eight grains. Furthermore, the main part of
Western foods is extensively processed; treatments like
growth enhancement, separation, condensing, drying,
freezing, irradiation, burning, microwaving, toasting,
adding various ingredients and especially heating are
often used. It is well-known that some important plant
ingredients start disappearing already when heated above
28 °C, important plant enzymes and microbes above 42
°C, dysfunctioning proteins are formed above 80 °C and
heterocyclic amines and also trans fatty acids from about
130 °C, and increasing as the heating of the food in-
creases further, all changes having negative effect on
human health.
Among the dysfunctioning proteins produced dur-
ing heating of foods are the so called Maillard products,
often referred to as advanced glycation and advanced
lipoxidation end products, and abbreviated as AGEs and
ALEs, respectively. Among foods rich in AGEs and ALEs
are: dairy products, especially powdered milk (frequent-
ly used in enteral nutrition and baby formulas, as well
as in numerous foods such as ice cream), cheese, bakery
products (bread crusts, crisp breads, pretzels, biscotti) and
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cereals (rice crispies), overheated (especially deep-fried
and oven-fried) meat and poultry but also fish, drinks
like coffee and Coca-Cola, Asian sauces including Chi-
nese soy sause, balsamico products and smoked foods
in general – for further information, see Goldberg et al.
(1) and Bengmark (2). The consumption of such foods,
often main constituents in fast foods, has increased dra-
matically in recent decades, much in parallel to the en-
demic of chronic diseases.
Deranged and Dysfunctioning Immune System
Numerous chemical substances, additives to foods
and pharmaceutical drugs seem to derange the immune
system. It is clear, even if not fully investigated, that a
large number of chemicals, when consumed, have a strong
negative influence on the immune system and the body's
resistance to disease. In the past, priority was not given
to the investigation of eventual negative effects of con-
sumed food additives and pharmaceutical drugs on the
innate immune systems. It has long been known that an-
tibiotics suppress various immune functions, and espe-
cially macrophage activities such as chemiluminescence
response, chemotactic motility, bactericidal and cytostat-
ic ability, and similar negative effects have also been seen
with other commonly used drugs such as H2-blockers,
proton inhibitors and surface-protection agents.
Several other factors increase the degree of systemic
inflammation in the body: impaired hormonal homeo-
stasis increases oxidative stress/release of free radicals,
intracellular accumulation of 'waste products', inhibits
apoptosis, disturbs repair mechanisms, reduces gene poly-
morphism, increases premature shortening of telomeres
and reduces immune defence and resistance to disease,
changes often observed in premature aging and in vari-
ous several chronic diseases (3); low level of vitamin D
in the body and subsequent secondary hyperparathy-
roidism (4); low levels of antioxidants in the body such
as folic acid and glutathione and increased levels of homo-
cysteine (5); high levels of estrogens in the body, espe-
cially 17b-estradiol, often induced by high consumption
of hormone-rich dairy products (6); high levels of an-
giotensin/rennin (7); and larger intake of glutenoids (8).
The reason why attempts to reduce inflammation
with the use of probiotics sometimes failed in the past
might be that the pro-inflammatory pressure is simply
too high due to the underlying disease, but also due to
the consumption of too much of pro-inflammatory foods
and prescription drugs, all with inflammation-enhancing
abilities. It is likely that under certain conditions, addi-
tional measures are needed in order to achieve success-
ful treatment with probiotics. Measures such as reduced
supply of pro-inflammatory foods, restriction in the use
of pharmaceuticals and increased intake of plant foods
rich in anti-inflammatory vitamins and antioxidants,
especially various polyphenols, might well be needed –
see further below.
Effects of Plant Fibres on Systemic Inflammation
It should be observed that various seeds, nuts, beans
and peas are especially rich in fibre, foods which no
longer are eaten in the quantities they deserve. A com-
mon recommendation of minimum daily fibre intake is
in the range of 30–35 g per day, which roughly corre-
sponds to about half a kg of fruits and vegetables, or, as
often expressed, 5 to 8 fresh fruits and vegetables per
day. The recommendations for children above the age of
2 are usually defined as age+5 g per day. No precise re-
commendation exists yet about the intake of fibre under
different conditions of disease. The daily intake of die-
tary fibre is unsatisfactory in all Western countries, espe-
cially among people with low level of education and low
income. In the US for example, the estimated daily in-
take of fibre is approx. 14–15 g per day or about 50 % of
what is recommended, and far below the 60–80 g per
day of substrate required to maintain a large bowel flora
of 1014 microorganisms, known to be typical for a healthy
and well-functioning human colon. Most Americans and
Europeans have lost the ability to maintain a large pro-
portion of what can be regarded as a natural flora (9). A
recent study in a North-European population has found
Lactobacillus plantarum, Lactobacillus rhamnosus and Lac-
tobacillus paracasei ssp. paracasei on the rectal mucosa of
healthy humans only in 52, 26 and 17 %, respectively
(10). The colonization rate with other, commonly milk-
-born probiotic bacteria, such as Lactobacillus casei, Lacto-
bacillus reuteri and Lactobacillus acidophilus was in the same
study only 2, 2 and 0 %, respectively.
Commonly consumed cooked roots and other starchy
vegetables or grains consumed as bread, cereals and
porridge, but also most of the fruits consumed in West-
ern countries contain relatively little fibre, usually no
more than 1–3 g per serving. The largest amount of
consumed plant fibre is provided by resistant starch
(raw potato, unripe green banana), which re-crystallize
when allowed to cool after cooking, especially import-
ant for potato and bread. The daily consumption of this
type of fibre varies from one individual to another with
several hundred per cent (approx. 8–40 g/day). The sec-
ond largest source of fibre is non-starch polysaccharides
(approx. 8–18 g/day). The third group of fibre is oligo-
saccharides (onions, artichoke, banana, chicory), which
although important for health, regrettably today are con-
sumed in much too small quantities (approx. 2–8 g/day)
(11).
Function of Dietary Fibres
Supplemented fibres are associated with several
health benefits. The best documented physiological
effects, in addition to providing energy and nutrients to
the host and flora, are that they:
• change mucosal structure, increase mucosal growth
and improve mucosal function;
• increase intestinal flora, relieve constipation, reduce
production of putrefactive gases and provide resist-
ance to invading microorganisms;
• reduce serum triglycerides, serum cholesterol and
VLD lipoproteins;
• reduce the glycemic response to eating;
• improve water and electrolyte balance and increase
bioavailability and absorption of minerals such as
Ca, Mg, Fe and Zn.
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Consumption of medical fibres should always be
regarded as a surrogate for not consuming enough fresh
fruits and vegetables. There is no solid information to
support that supplementation of medical fibres to healthy
individuals eating a diet rich in fruits and vegetables is
associated with additional health benefits. Medical fibres
are mainly needed because the individual has lost the
ability to consume enough fresh fruits and vegetables.
This is often the situation in persons with severe allergy,
in old and debilitated persons and in persons with some
GI disorders, such as short bowel syndrome and ad-
vanced diverticular disease. This is also most often the
condition of critically ill patients, for whom enteral supply
of concentrates of medical fibres has become a most valu-
able clinical tool. It must, however, always be remem-
bered that during processing bioactive fibres lose numer-
ous important antioxidants and nutrients, some of which
when possible should be separately supplemented, and
whenever possible complemented with the supply of
fresh fruits and vegetables.
Health Benefits of Increased Plant Fibre
Consumption
Significant information on beneficial effects from
increased intake of plant fibres and so-called prebiotics
exists mainly for two large groups of diseases, described
in the following chapters.
Blood glucose control/prevention of type 2 diabetes
Fibre is a slow release system for delivery of glucose
to the body. Fibre, regularly supplied to patients with dia-
betes, will significantly reduce the level of blood glucose
and the need of insulin. Studies suggest that the most
pronounced effects of fibres on glycemic index are ob-
tained by water-soluble fibres. Guar gum is in this re-
spect by far the most clinically tried fibre and will, as
based on 15 different studies, reduce blood glucose to
almost half (44 %).
Lipid control/prevention of coronary heart disease
Soluble fibres such as pectin, guar gum, b-glucans
(oat) reduce significantly blood cholesterol both in hyper-
cholesterolemic and normocholesterolemic individuals,
effects not found when non-soluble fibres such as cellu-
lose and wheat bran are tried. Soluble fibres are excel-
lent substrates for the production of short chain fatty
acids (SCFAs) in the large intestine, known to reduce the
levels of cholesterol(s) in the body.
A meta-analysis reports statistically significant pro-
tective effects against coronary heart disease in 14 out of
16 studies (12). In addition, fibre consumption will also
reduce clotting and increase fibrinolysis, also important
for prevention of building of arterial wall plaques and
prevention of thrombosis formation.
Clinical Use of Fibres
Substances important for health: amino acids such
as arginine, glutamine, histidine, taurine, various sul-
phur and related amino acids, polyamines, w-fatty acids,
numerous vitamins and antioxidants are all to a great
extent supplied to the body from plants. One cannot ex-
pect any significant amount of antioxidants to be deliv-
ered to the lower level of the gastrointestinal tract if not
'hidden' in plant fibres. It is important to remember that
key nutrients such as w-3 fatty acids, glutamine, gluta-
thione and several other nutrients are heat-sensitive and
do not tolerate processing or storage to any larger ex-
tent. Plant fibres, which have been dried, heated up or
microwaved cannot be expected to contain any larger
amounts of these; they do mainly come with unpro-
cessed foods. It is highly desirable that, whenever pos-
sible, the supply of commercial nutrition formulas is com-
plemented with the supply of fresh fruit and vegetable
juices, as locally produced as ever possible. It is also de-
sirable that several fibres are supplied in parallel, and
that both soluble and non-soluble fibres are used. For
example, oat fibres are mainly metabolized in the proxi-
mal colon, while wheat fibres are known to be effective
in the distal part of the colon, e.g. the part of the colon
where most cancers are localized. Oat has mainly shown
sepsis-reducing effects, while wheat has mainly been
effective in cancer prevention.
Among the fibres commonly used in clinical nutri-
tion are:
Algal fibres
Most of the algal fibres are resistant to hydrolysis by
human endogenous digestive enzymes, but are to vari-
ous degrees fermented by colonic flora. The soluble fi-
bres consist of lamarans (a sort of b-glucan associated
with mannitol residues), fucans (sulphated polymers asso-
ciated with xylose, galactose and glucuronic acid) and
alginates (mannuronic and guluronic acid polymers). The
insoluble algal polymers consist mainly of cellulose. Fer-
mentation of alginates yields high levels of acetate (80
%), while lamarans yield preferably butyrate (16 %). It is
most likely that algal fibres will within a few years be
routinely used in clinical nutrition.
Fructans
Fructans, starches and sucrose serve in the plant as
its energy reserve. These substances are also produced
by bacteria and fungi. Fructans are said to enhance the
tolerance of the plant to stressful conditions and make it
possible for the plants to survive under harsh condi-
tions, such as low temperature and draft. The most well-
-known fructans are inulin (rich in chicory, artichoke,
onions, and banana) and phleins (rich in various grass-
es). So far inulin has mainly been used in human nutri-
tion. Various oligosaccharides are reported to stimulate
the flora and especially the growth of Lactobacillus and
Bifidobacterium in the large intestine and to reduce the
content of potentially pathogenic microorganisms (PPMs)
in the intestine. Increase in the Bifidobacterium flora is re-
garded as especially favourable since bifidobacteria are
known to produce important vitamins, among them thia-
mine, folic acid, nicotinic acid, pyridoxine and vitamin
B12, which is of great importance for health. A fructan
called neokestose, found in onion, is reported to have
even better ability than inulin to promote the growth of
lactic acid bacteria (LAB). Also, supplementation of fruc-
tans is reported to reduce concentrations in serum of
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insulin, cholesterol and triacylglycerol. It is also report-
ed to promote the absorption of calcium and other min-
erals. Other oligosaccharides such as those extracted from
peas and beans, especially soya bean oligosaccharide
(raffinose and stachyose) and pyrodextrin, produced by
pyrolysis of maize and potato starch, are also reported
to be beneficial for human health.
Glycomannans
Glycomannan is a glucose/mannose polymer de-
rived from a plant called Amorphophallus konjak, which
has several English names such as devil's tongue, ele-
phant yam and umbrella arum. It has unique hydro-
scopic abilities and in contact with water it swells and
forms a viscous gel, which, like other gels, delays gastric
emptying and intestinal transit time. It has been shown
to be effective in delaying absorption of digestible ener-
gy. It has this far mainly been used in Japan and other
Asian countries to treat diabetes, hypertension and hyper-
cholesterolemia. Dietary supply of konjak mannans has
been shown to alter the flora and reduce tumorigenesis
in experimental animals. It is also effective in the control
of diarrhoea in enteral nutrition, especially in elderly
patients, and in the increase of the Bifidobacterium flora.
Oat gum
Oat contains a series of interesting compounds, which
is the reason why an increasing part of the world pro-
duction of oat goes to the pharmaceutical and cosmetic
industries. The amino acid pattern of oat is rather simi-
lar to that of human muscle (only that of buckwheat is
more alike), and can thus be expected to deliver most of
the amino acids needed to build muscles. Oat is rich in
water-soluble fibres, b-glucans, and is known for its anti-
septic properties. It is also rich in natural antioxidants,
particularly ferulic acid, caffeic acid, hydrocinnamic acid,
and tocopherols. Also, before synthetic antioxidants were
available, oat was extensively used to preserve foods:
milk, milk powder, butter, ice cream, fish, bacon, sau-
sages and other food products sensitive to fat oxidation.
Another ingredient richly available in oat is inositol hexa-
phosphate (phytic acid), a strong antioxidant, particular-
ly known to enhance natural killer cell activity and to
suppress tumour growth. Oat is also rich in polyunsat-
urated fats/polar lipids such as phosphatidylcholine,
known for their protective effects of mucosal and cel-
lular surfaces.
Pectin
Pectin is also an interesting fibre, extensively used
by pharmaceutical and food industry. It has a unique abi-
lity to form gels and is commonly used as a carrier of
pharmacologically active substances and in baby foods.
An important finding is that pectin is a very strong
antioxidant against the three most dominant oxidation
damages induced by peroxyl, superoxide and hydroxyl
radicals. These effects might explain why pectin has the
capacity to stimulate the gut-associated immune system
and to prevent disruption of the intestinal microflora.
Pectins have shown strong protective and healing effects
on gastric but also intestinal mucosa in experimental
studies not inferior to what is observed with H2-block-
ers, proton inhibitors and surface-protection agents (13,
14). Pectin builds a protection layer in the stomach and
facilitates maintenance of gastric acidity, important for
prevention of colonization of the stomach by pathogens.
Pectin is also an excellent substrate for microbial fermen-
tation.
Lactic Acid Bacteria as a Key to the
Fermentation of Fibres
Not all fibres are easily fermented in the gut. Among
the more fermentation-resistant fibres are wheat fibres,
which are usually not digested until they reach descend-
ing colon. Also, oligofructans (inulin or phleins) are dif-
ficult to ferment and only a small minority of LAB are
able to do so. When the ability of 712 different LAB to
ferment oligofructans was studied, only 16 were able to
ferment the phleins and 8 to ferment inulin (15). Apart
from Lactobacillus plantarum, only three other LAB spe-
cies, Lactobacillus paracasei ssp. paracasei, Lactobacillus bre-
vis and Pediococcus pentosaceus, were able to ferment these
semi-resistant fibres. Another study investigated the abil-
ity of 28 different LAB to ferment pure fructooligosacha-
rides (FOS). All L. plantarum, L. casei and L. acidophilus
strains studied and most bifidobacteria metabolized FOS,
in contrast to yoghurt bacteria such as L. bulgaricus and
Streptococcus thermophilus and also Lactobacillus strain GG,
which were all unable to ferment these fibres (16).
Clinical Experience with Supplemented Plant
Fibres
Plant fibres in constipation
Chronic constipation is one of the most common dis-
orders in Western countries. Its aetiology remains un-
clear despite numerous clinical, pathophysiologic, and
epidemiologic studies, but it is suggested that high in-
take of dairy products and intake of plant fibres play a
significant role in its pathogenesis. A randomized sample
of 291 children with idiopathic chronic constipation was
compared in a case control study with 1602 healthy con-
trols (17). Constipation was clearly negatively correlated
with low intake of cellulose and pentose fibres (p<0.001).
Fructooligosaccharides (FOS) may also have potential
benefits in constipation, since they exhibit many soluble
dietary fibre-like properties. In a study a total of fifty-six
healthy infants, aged 16–46 weeks (mean age 32 weeks)
were randomly assigned to receive either 0.75 g of FOS
or placebo added to a serving of cereals for 28 days (18).
The mean number of stools per infant was 1.99±0.62 per
day in the FOS-supplemented group compared with
1.58±0.66 in the control group (p=0.02).
Plant fibre to prevent and treat diarrhoea
In a large randomized study in acutely ill medical
and surgical patients, all requiring enteral nutrition for a
minimum of 5 days, supplementation of hydrolyzed guar
gum was compared to a fibre-free enteral nutrition, the
incidence of diarrhoea being 9 % with fibre-supplemen-
tation, compared to 32 % with fibre-free nutrition (p>0.05)
(19). One of the effects of certain fibres is that they in-
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crease the bioavailability and absorption of zinc, which
is especially shown for oligosaccharides. Zink supple-
mentation was in a randomized study in 3- to 59-month-
-old children in Bangladesh proven effective in lowering
both the incidence of diarrhoea and its duration (20). In
another study from Bangladesh, 250 g/L of green (un-
ripe) banana (equivalent to two fruits) or 2 g pectin/kg
food were supplemented to a rice diet in children suffer-
ing from persistent diarrhoea (21). The amounts and fre-
quency of stools, the duration of diarrhoea, numbers of
vomiting, use of oral rehydration and amounts of given
fluid solutions were all significantly reduced in both cases,
supplementation with green banana and pure pectin.
Recovery on the third day was seen in 59 % in the green
banana group, in 55 % in the pectin group, compared to
15 % in the rice only control group.
Plant fibre to support mineral absorption
It is well accepted that nutrition is of great impor-
tance for bone health. Most of the interest has this far
focused on calcium and vitamin D. Much less interest
has been paid to other important nutrients such as pro-
tein, and especially to minerals such as phosphorus, potas-
sium, magnesium and vitamins such as C and K. Recent
studies suggest that increased intake of plant fibres,
fruits and vegetables is associated with an increased bone
mineral density also in elderly subjects, both women
and men (22,23). Of pure fibres available, mainly the
effects of oligosaccharides have been studied, and main-
ly in experimental animals, while calcium absorption,
bone calcium content, bone mineral density, bone balance
and bone formation/bone absorption index have been
reported to significantly increase already after three weeks
of supplementation of a mixture of inulin and fructo-
oligosaccharides.
Plant fibre to control mass
No major effects on body mass by supplementation
of only prebiotic fibre have this far been reported. The
effects of dietary fibre on subjective hunger ratings and
weight losses were studied some twenty years ago in
members of a weight loss club. One hundred and eight
of 135 members completed the trial: 23 controls, 45 on
ispaghula granulate and 40 on bran sachets (24). Both
fibre preparations reduced hunger at all meals. The
mean±S.D. mass reductions during the trial were (4.6±2.7)
kg for the controls, (4.2±3.2) kg for the ispaghula group
and (4.6±2.3) kg for the bran group (p>0.05 for both
groups). Although supply of dietary fibre immediately
before meals did reduce the feeling of hunger, it did not
provide any additional benefits to the weight reduction.
A more recent crossover study compared the effect on
satiety of supplementation of (27±0.6) g/day of ferment-
able fibres (pectin, b-glucan) with similar amounts of non-
-fermentable fibre (methylcellulose). The daily satiety was
increased more significantly with non-fermentable (meth-
ylcellulose) than with fermentable fibres (b-glucan, pec-
tin) (p=0.01), but no differences were observed in daily
energy intake or loss of body mass or body fat (25).
Plant fibre in inflammatory bowel diseases (IBD)
Although both patients with IBD and irritable bow-
el syndrome (IBS) are known to under-consume dietary
fibres, there is little evidence that the lack of dietary
fibre plays a role in the pathogenesis of these diseases.
The ability of maintaining remission in ulcerative colitis
(UC) patients by a daily supply of 10 g of Plantago ovata
seeds (also called psyllium or ispaghula husk) was com-
pared with daily treatment with 500 mg of mesalamine
and a combination of the two (26). Twelve months of
treatment failed to demonstrate any difference in clinical
benefits between the three groups. Germinated barley
foodstuff (GBF), a by-product from breweries, rich in
hemicellulose and in glutamine, was tried in 39 patients
with mild-to-moderate active UC (27). Daily supply of
30 g reduced significantly the disease activity, increased
the concentration of short-chain fatty acids (SCFAs), and
increased the numbers of Bifidobacterium and Eubacterium
in the stool. It can well be that the observed effect was
more due to increased supply of glutamine and other
antioxidants such as various B vitamins than to the fibre
per se as these compounds are known to be rich in by-pro-
ducts from breweries. Glutamine, as well as other anti-
oxidants, is known to attenuate pro-inflammatory cyto-
kines such as TNF-a and to enhance the release of heat
shock proteins (HSP-72) (28). A controlled study using
oat bran as fibre source was recently reported from a
study in 22 patients+10 controls with quiescent UC. Daily
supply during three months of as much as 60 g of oat
bran (equivalent to 20 g of dietary fibres) resulted in a
significant increase in faecal butyrate (36 % average) but
also in reduction in abdominal pain. All the treated pa-
tients tolerated well the large dose of fibre and signs of
relapse of disease were seen in none of the colitis pa-
tients (29). Butyrate has been shown to inhibit NF-kB
activation of lamina propria macrophages, and to reduce
the number of neutrophils in crypts and surface epithe-
lia, as well as the density of lamina propria lympho-
cytes/ plasma cells in patients with ulcerative colitis (30)
– findings correlating well with the observed decreased
disease activity. Twenty patients with ileal pouch-anal
anastomosis received 24 g of inulin daily for two weeks.
Significant reduction in inflammation was observed with
endoscopy and histology. In addition, significant increase
in faecal butyrate concentrations and reductions in fae-
cal pH, faecal content of secondary bile acids, and growth
of Bacteroides fragilis were observed (31).
Plant fibre in irritable bowel disease
Dysmotility disorders are increasingly common in
Western societies. Some evidence suggests that various
dysmotility disorders, gastroesophageal reflux problems,
infant colic and constipation are all food-related features,
and often due to intolerance to cow's milk proteins (32).
Irritable bowel syndrome (IBS) is a clinical diagnosis
based on the occurrence of abdominal distension, abdom-
inal cramps, often increased transit time, more frequent
stools, and relief of pain on defecation. The prevalence
of the syndrome varies between 7 and 22 %, making IBS
the most common functional gastrointestinal disorder
(33). Unfortunately, no effective pharmaceutical treat-
ment exists or if existing is unacceptably toxic (34). This
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has resulted in a need for additional modalities for the
treatment of IBS. Pre- and probiotics appear in this per-
spective as attractive alternatives, see further reviews (35,
36), especially as early data from human intervention
studies and especially results from recent animal studies
clearly indicate that prebiotics have an impact on the
immune system: immune cells of the gut-associated lym-
phoid tissue (GALT) including Peyer's patches are pri-
marily responsive to the oral administration of prebiotics
(37). However, a consequence of feeding the currently
favoured prebiotics (inulin, fructooligosaccharides (FOS),
trans-galactooligosaccharides and lactulose) is increased
gas production in the gut, which might preclude pre-
biotic use in diarrhoea-predominant IBS, or where bloat-
ing or gas are prominent symptoms, but might allow
their mild laxative properties to be useful in constipation-
-predominant IBS (38). During the years some small
open trials have been performed, but this far, no larger
and randomized trial has been reported. However, a re-
cent small open label trial supplementing 15 g/day of a
mixture of oligofructose (70 %) and inulin (30 %) reports
significant reduction in disease activity (Harvey-Brad-
shaw index fell from 9.8, S.D.=3.1, to 6.9, S.D.=3.4, p<0.01)
in parallel to a significant increase in faecal bifidobac-
teria concentration (from 8.8, S.D.=0.9, log to 9.4, S.D.=
0.9, log cells/g dry feces, p<0.001). Also the IL-10 posi-
tive dendritic cells increased (from 30 to 53 %, p=0.06),
and the percentage of dendritic cells expressing TLR2 and
TLR4 increased from 1.7 to 36.8 %, p=0.08, and from 3.6
to 75.4 %, p<0.001), respectively (38), which offers hope
for the future.
Plant fibre in abdominal pain
Other dietary fibres have also been tried in various
groups of abdominal pain. A recent Cochrane review
was unable to find any evidence that fibre supplements,
lactose-free diets or lactobacillus supplementation are
effective in the management of children with recurrent
abdominal pain (39). However, a study in adult patients
reports significant success with other fibres than the
classical prebiotics. One hundred and eighty-eight adult
IBS patients were classified as having diarrhoea-predo-
minant, constipation-predominant, or changeable bowel
habits and were randomly assigned to groups receiving
30 g/day of wheat bran or 5 g/day of partially hydro-
lyzed guar gum (PHGG) (40). After four weeks, patients
were allowed to switch group, depending on their sub-
jective evaluation of their symptoms. Both fibres and
PHGG were effective in improving pain and bowel hab-
its. Significantly more patients switched from fibre to
PHGG (49.9 %) than from PHGG to fibre (10.9 %) at four
weeks. Intention-to-treat analysis showed a significantly
greater success in the PHGG group (60 %) than in the
fibre group (40 %). In addition, significantly more pa-
tients in the PHGG group reported a greater subjective
improvement than those in the fibre group. It was con-
cluded that improvements in core IBS symptoms were
observed with both bran and PHGG, but the latter was
better tolerated and preferred by patients (40).
Plant fibre to control infections
In an effort to prevent nosocomial pneumonia and
sepsis, patients with severe multiple trauma were treat-
ed with b-1,3-polyglucose (glucan) – a component of cell
walls of plants and microbes (41). Pneumonia occurred
in 2 out of 21 glucan-treated and in 11 out of 20 patients
in the control group (p<0.01). Infectious complications
(pneumonia and/or general sepsis) occured in 14 % of
glucan-supplemented patients vs. 65 % in the control
group (p<0.001). Another study compared the effects of
a high-protein formula enriched with fibre but also argi-
nine, and antioxidants with a standard high-protein
formula in early enteral nutrition in critically ill patients
(42). The supplemented group had, in comparison with
non-supplemented controls, a lower incidence of cath-
eter-related sepsis (0.4 episodes/1000 ICU days) than the
control group (5.5 episodes/1000 intensive care unit (ICU)
days) (p<0.001), but no differences in the incidence of
ventilator-associated pneumonia (VAP), surgical infection,
bacteremia, urinary tract infections, mortality and in long-
-term survival were observed between the groups (42).
Pre-, Pro- and Synbiotics Improve Innate
Immunity
Several plant fibres (prebiotics) and a few LAB (pro-
biotics) have documented significant effects to improve
the function of the innate immune system, the physical
barrier, and increase resistance to disease. The hope is
that combined supply of these components shall have
synergistic rather than additive effects in boosting the
immune system and enforcing the barrier functions. Pro-
ducts which combine pre- and probiotics are called syn-
biotics and treatments using the combination are called
synbiotic treatments.
Choice Strains for Probiotic Use
The choice of pre- and probiotics must be based on
scientific evidence. Stronger bioactivities cannot be ex-
pected from LAB such as yoghurt bacteria, chosen mainly
for their palatability. The strains to use must be done
with care and extensive preclinical studies are necessary
prerequisites.
It is important to remember that the majority of LAB
have much limited or no effects on the immune func-
tions and outcome. Constructing synbiotic formulations
is especially demanding as most of the LAB used by in-
dustry have limited or no ability to ferment bioactive
fibres such as inulin or phlein (15), no ability to adhere
to human mucus, have low antioxidant capacity and,
most importantly, do not survive the acidity of stomach
and bile acid content.
It has been observed that strains that carry the same
name have different and sometimes opposing functions.
A recent study has investigated the ability of 46 different
Lactococcus lactis strains to induce the production of the
cytokines interleukin (IL)-6, IL-12 and tumor necrosis
factor (TNF)-a. The extent of induction of IL-6, IL-12
and TNF-a was shown to be strain-specific and was not
related to species, bio-variety, or the source of the iso-
late. The production of IL-6 varied between 138 and 0
ng/mL, of IL-12 between 3 and 0 ng/mL and of TNF-a
between 20 and 0 ng/mL (43).
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Unfortunately, few studies have looked at the syner-
gistic effects of simultaneous supply of LAB and fibres –
synbiotics. Natural foods supply both LAB and a great
variety of plant fibres. Combination of several fibres has
been shown to lead to additive effects on microbial eco-
system and immune responses (44), and multi-species pro-
biotics are documented to be superior to single-species
probiotics, showing increased ability to enhance growth,
reduce antibiotic-associated diarrhoea, to prevent infec-
tions (S. typhimurium) and reduce pathogenic colonisa-
tion (E. coli) (45). Although some studies have used vari-
ous synbiotic compositions, only two such compositions
have been produced after extensive preclinical studies:
(i) A unistrain/unifibre composition (Probi AB, Lund,
Sweden), produced by fermentation of oatmeal with L.
plantarum strain 299, containing 109 of LAB and approx.
10 g of oat fibre (46). In a few studies a commercial fruit
juice ProViva™ containing 107 of a related L. plantarum
strain called 299V (Skånemejerier, Malmö, Sweden) is
also tried.
(ii) A multistrain/multifibre composition, called Syn-
biotic 2000™, consisting in a mixture of 1010, and a Syn-
biotic Forte™ with 1011 of each of four LAB: Pediococcus
pentosaceus 5–33:3, Leuconostoc mesenteroides 32–77:1, Lac-
tobacillus paracasei ssp. paracasei 19, and Lactobacillus plan-
tarum 2362, and 2.5 g of each of the four fermentable fibres
(prebiotics): b-glucan, inulin, pectin and resistant starch
(Synbiotic AB, Höganäs, Sweden) (47,48).
Lund University microbiologists Åsa Ljungh and Tor-
kel Wadström developed this multi-strain/multi-fibre
synbiotic formula, which in recent years has been exten-
sively used in clinical trials. The choice of LAB for the
formulation was done after extensive studies of more than
350 human (47) and more than 180 plant microbial strains
(48) and based especially on the ability of the LAB to
produce bioactive proteins, transcribe NF-kB, produce pro-
and anti-inflammatory cytokines, produce antioxidants,
and most importantly, to functionally complement each
other. In recent studies, both Synbiotic 2000 Forte™ and
Probiotic 2000 Forte™ (no fibre added), containing 1011
of each of the four LAB, e.g. 400 billion LAB per dose,
have been tried.
Plantarum, Paracasei and Pediococcus
As mentioned above, when the ability of 712 differ-
ent LAB to ferment oligofructans was studied, only 16
were able to ferment semi-resistant fibres, phleins, and 8
fermented inulin; identified as Lactobacillus plantarum, Lac-
tobacillus paracasei ssp. paracasei, Pediococcus pentosaceus
and Lactobacillus brevis (15). Interesting clinical results
are also often obtained when these LAB are involved.
When more than 100 LAB were compared, L. paracasei
ssp. paracasei were demonstrated to be the strongest in-
ducer of Th1 and repressor of Th2 cytokines (49). Sever-
al other studies have also documented the unique abil-
ity of L. paracasei to induce cellular immunity, stimulate
production of suppressive cytokines as TGF-b and Il-10,
suppress CD4 T-cells, Th2 activity, splenocyte prolifer-
ation and decrease antigen-specific IgE and IgG1 (50–53).
The effect of Lactobacillus paracasei (NCC 2461), Lac-
tobacillus johnsonii (NCC 533) and Bifidobacterium lactis
Bb12 (NCC 362) on the induction and maintenance of
oral tolerance to bovine b-lactoglobulin (BLG) was in-
vestigated in mono-colonized germfree mice. The effects
of L. paracasei were reported superior to those of the other
two (53). A study which compared the ability of 50 dif-
ferent LAB to control 23 different pathogenic Clostridium
difficile found more than half (27 out of 50) totally inef-
fective, 18 antagonistic to some, but only five strains
effective against all: two strains of L. paracasei ssp. para-
casei and three strains of L. plantarum (54). Another study
compared the effects of either Lactobacillus paracasei, Lac-
tobacillus johnsonii, Bifidobacterium longum, or Bifidobac-
terium lactis in rats during 10 to 21 days after Trichinella
spiralis-induced infection; L. paracasei but not the other
LAB attenuated muscle hypercontractility, reduced the
infection-associated Th-2 response and muscle levels of
TGF-b, COX-2 and PGE2 (55). A recent study on animals
compared the effects of three probiotic strains: Bifidobac-
terium lactis NCC362, Lactobacillus johnsonii NCC533 and
Lactobacillus paracasei NCC2461 on stress-induced changes
in gut permeability and on sensitivity to colorectal dis-
tension (CRD). Only L. paracasei reduced significantly
the existing visceral pain and also restored normal gut
permeability (56).
Synbiotic 2000 in Clinical Medicine
During the last two decades I have studied the effects
of synbiotic compositions in various clinical situations,
during the 1990s the monostrain/monofibre composition,
mentioned above, and in the 2000s the multistrain/mul-
tifibre composition, also mentioned above; Synbiotic 2000
and 2000 Forte. Here follows a summary of the effects
observed this far. It has been tried under the following
conditions:
Acute pancreatitis
Sixty-two patients with severe acute pancreatitis (SAP)
(Apache II scores: Synbiotic 2000-treated 11.7±1.9, con-
trols 10.4±1.5) were given either two sachets per day of
Synbiotic 2000™ (2×40 billion LAB per day and totally
20 g of fibres) or the same mass of fibres (20 g) as in
Synbiotic 2000™ during the first 14 days after arrival to
hospital (57). Out of 33 patients in the Synbiotic 2000-
-treated group and 29 patients in the fibre-treated group,
nine (27 %) and 15 (52 %) developed subsequent infec-
tions respectively, while eight (24 %) of the Synbiotic
2000-treated and 14 (48 %) of the fibre-treated patients
developed systemic inflammatory response syndrome
(SIRS), multiple organ failure (MOF) or both (p<0.005).
A total of seven pathogenic microorganisms were cul-
tivated in the Synbiotic-treated group compared to seven-
teen in the fibre-treated group (Table 1).
Polytrauma
Two prospective randomized trials, one with Syn-
biotic 2000 and one with Synbiotic 2000 Forte have been
concluded. The first study in patients with acute exten-
sive trauma compared Synbiotic 2000 (40 billion LAB/
day) with soluble fibre, a peptide diet (Nutricomp, Braun
Inc, Germany) with supplementation of glutamine treat-
ments. Treatment with Synbiotic 2000™ led to a highly
significant decrease in the number of chest infections (4
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out of 26 patients, 15 %), compared to peptide diet (11
out of 26 patients, 42 %, p<0.04), glutamine (11 out of 32
patients, 34 %, p<0.03) and fibres (12 out of 29 patients,
41 %, p<0.002) (58). Also, the total number of infections
was significantly decreased: 5 out of 26 patients (19 %)
treated with Synbiotic 2000™, 17 out of 29 patients (59
%) with fibres, 13 out of 26 patients (50 %) with peptide
and 16 out of 32 patients (50 %) with glutamine.
In the second study, sixty-five polytrauma patients
were randomized to receive once daily for 15 days Syn-
biotic 2000 Forte (400 billion LAB+10 g of fibres, see
above) or maltodextrine as placebo. Significant reduc-
tions were observed in the number of deaths (5/35 vs.
9/30, p<0.02), severe sepsis (5/35 vs. 13/30, p<0.02), chest
infections (19/35 vs. 24/30, p<0.03), central line infec-
tions (13/32 vs. 20/30, p<0.02), and ventilation days
(average 15 vs. 26 days) (59). A total of 54 pathogenic
microorganisms were cultivated in the Synbiotic-treated
group compared to 103 in the placebo group. The time
of progression of primary bacteraemia was longer among
patients treated with Synbiotic 2000 Forte compared with
placebo (p=0.0237 between groups). Twelve (33.3 %) and
five (13.9 %) placebo- and synbiotic-treated patients, re-
spectively, developed ventilator-associated pneumonia
with Acinetobacter baumannii as a bacterial cause (p=0.047
between groups). Treatment with Synbiotic 2000 Forte
was accompanied by reduction of white blood cell counts
and lipopolysaccharide (LPS) and C-reactive protein (CRP)
levels in patients who either did or did not develop
sepsis (60).
Abdominal surgery
In a randomized controlled study, forty-five patients
undergoing major surgery for abdominal cancer were
divided into three treatment groups: (i) enteral nutrition
(EN)+Synbiotic 2000 (LEN), (ii) EN+only the fibres of
the same mass (20 g) as in Synbiotic 2000™ (FEN), and
(iii) a standard parenteral nutrition (PN). All treatments
lasted for 2 preoperative and 7 postoperative days. The
incidence of postoperative bacterial infections was 47 %
with PN, 20 % with FEN and 6.7 % with LEN (p<0.05)
(personal information). A total of 34 pathogenic micro-
organisms were cultivated in the Synbiotic-treated group
compared to 54 in the fibre-only group. Significant im-
provements were also documented in prealbumin (LEN,
FEN), C-reactive protein (LEN, FEN), serum cholesterol
(LEN, FEN), white cell blood count (LEN), serum endo-
toxin (LEN, FEN) and IgA (LEN).
In another prospective randomized double-blind trial
performed on 80 patients subjected to pylorus-preserv-
ing pancreatoduodenectomy (PPPD), they received twice
daily either Synbiotic 2000TM (2×40 billion LAB) or only
fibres from the day before surgery and during the first
seven postoperative days (61). A highly significant dif-
ference in infection rate (p=0.005) was observed as only
5 out of 40 patients (12.5 %) in the Synbiotic 2000-treated
group suffered infections (4 wound and one urinary tract
infection) vs. 16 out of 40 (40 %) in the fibre-treated group
(6 wound infections, 5 peritonitis, 4 chest infections, 2
sepsis, and one of each of urinary tract infection, cho-
langitis and empyema). The infecting microorganisms in
the Synbiotic-treated group were: Klebsiella pneumoniae (2
patients), Enterobacter cloacae (2 patients), Proteus mirabi-
lis (1 patient) and Enterococcus faecalis/faecium (1 patient)
and in the fibre-treated group Enterobacter cloacae (8 pa-
tients), Enterococcus faecalis/faecium (7 patient), Escherichia
coli (7 patient), Klebsiella pneumoniae (2 patients), Staphy-
lococcus aureus (2 patients), and Proteus mirabilis (1 pa-
tient), Table 2. Statistically significant differences between
the groups were also observed in the use of antibiotics
(mean: Synbiotic 2000 (2±5) days, fibre-treated (10±14)
days).
Chronic liver disease and liver transplantation
Fifty-eight patients with liver cirrhosis suffering from
the so-called minimal encephalopathy were randomized
into three treatment groups: group 1 (20 patients) re-
ceived Synbiotic 2000 (40 billion LAB), group 2 (20 pa-
tients) received the same amount of fibres in Synbiotic
2000 and group 3 (15 patients) received placebo (non-
-fermentable, non-absorbable fibre – crystalline cellulose)
(62). A significant increase in intestinal LAB flora was
observed after one month of supplementation in the Syn-
biotic-treated group, but not in the other two groups. In-
testinal pH was significantly reduced in both treatment
groups but not in the placebo-treated group. Significant
decreases in faecal Escherichia coli, Staphylococcus and
Fusobacterium counts, but not in Pseudomonas and Entero-
coccus, and significant decreases in ammonia, endotoxin,
ALT and bilirubin (original level 252±182) were observed
in the Synbiotic 2000-treated group (84±65, p<0.01) and
in the fibre-treated group (110±86, p<0.05), while it re-
mained unchanged in the placebo group. The improve-
ments in liver function were accompanied by significant
improvements in psychometric tests and in the degree
of encephalopathy.
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Table 1. Isolated bacteria in acute pancreatitis treated with Syn-
biotic 2000 or fibres
Isolated bacteria Synbiotic-treated Fibre-treated
Enterococcus faecalis 1 11
Escherichia coli 0 3
Enterobacter cloacae 0 2
Pseudomonas aeruginosa 0 2
Staphylococcus aureus 0 1
Total 1 18
Table 2. Isolated bacteria in patients undergoing pancreatoduo-
denectomy and treated with Synbiotic 2000 or fibres
Isolated bacteria Synbiotic-treated Fibre-treated
Enterobacter cloacae 2 8
Enterococcus faecalis/faecium 1 7
Escherichia coli 0 7
Klebsiella pneumoniae 2 2
Proteus mirabilis 1 1
Staphylococcus aureus 0 2
Total 6 27
In a follow-up study by the same group of investi-
gators 30 patients with liver cirrhosis were randomized
to receive either Synbiotic 2000 or placebo (crystalline cel-
lulose) for 7 days (63). Viable fecal Lactobacillus sp. counts,
Child-Pugh class, plasma retention rate of indocyanine
green (ICGR15), whole blood tumour necrosis factor alpha
(TNF-a) mRNA and interelukin-6 (IL-6) mRNA, serum
TNF-a, soluble TNF receptor (sTNFR)I, sTNFRII and IL-6
and plasma endotoxin levels were measured pre- and
post-treatment: synbiotic treatment was associated with
significantly increased faecal Lactobacillus counts and sig-
nificant improvements in plasma retention rate of ICGR15
and stage of liver disease (Child-Pugh classification). No
significant changes in any study parameter followed pla-
cebo treatment, but significant increases in whole blood
TNF-a mRNA and IL-6 mRNA, along with serum levels
of soluble TNF receptors sTNFRI and sTNFRII were ob-
served in the Synbiotic 2000-treated patients. TNF-a and
IL-6 levels correlated significantly, both at baseline and
post-synbiotic treatment. Synbiotic-related improvement
in ICGR15 was significantly associated with changes in
IL-6, both at mRNA and protein levels, and unrelated to
plasma endotoxin values. It was concluded that even
short-term synbiotic treatment can significantly modu-
late gut flora and improve liver function in patients with
cirrhosis. The observed benefits seemed unrelated to re-
duction in endotoxaemia, but could be mediated, at least
in part, by treatment-related induction of IL-6 synthesis
by TNF-a. These results offer great hope that synbiotic
treatment of patients on waiting list for liver transplan-
tation might prevent septic episodes, improve liver func-
tion, and promote successful outcome of surgery.
Sixty-six patients waiting for orthotopic liver trans-
plantation were randomized to either receive Synbiotic
2000 or synbiotic composition only with fibres. The treat-
ment started already on the day before surgery and con-
tinued for 14 days after the surgery. During the first
postoperative month only one patient in the Synbiotic
2000-treated group (3 %) showed signs of infection (uri-
nary infection) compared to 17 out of 33 (51 %) in the
patients supplemented with only four fibers (64). The
infecting organisms in the Synbiotic-treated group were
Enterococcus faecalis in 1 patient and in the fibre-treated
group Enterococcus faecalis/faecium in 11, Escherichia coli in
3, Enterobacter cloacae in 2, Pseudomonas aeruginosa in 2
and Staphylococcus aureus in 1 patient (Table 3). The use
of antibiotics was on average (0.1±0.1) day in the Syn-
biotic-treated patients and (3.8±0.9) days in the fibre-
-treated group.
Inflammatory bowel disease
Daily rectal instillations with Synbiotic 2000 recon-
stituted in saline were given to ten patients with distal
colitis during 2 weeks. One patient withdrew after one
week, the remaining patients showed dramatic improve-
ments in various disease scores during the 3 weeks of
observation; episodes of diarrhoea (2.4Þ0.8), visible blood
in stool (2.2Þ0.8), nightly diarrhoea (0.5Þ0), urgency
(1.9Þ1.0) and consistency of stool (1.1Þ0.8) (65). Two
patients reported significant bloating and wind but no
other adverse or side effects were reported.
Treatment-Resistant Conditions
Treatment with synbiotics has not this far improved
the conditions of disease in two groups of patients: (i)
inflammatory bowel disease – Crohn's Disease (CD): after
an initial treatment with infliximab, sixty-three patients
were randomized to receive daily either Synbiotic 2000
or crystalline cellulose as placebo (66). Median time to
relapse was 9.8 and 10.1 months, respectively. In a se-
cond study, following surgery the patients were supple-
mented with either Synbiotic 2000 or crystalline cellu-
lose as placebo. Seven patients in the synbiotic-treated
group and two in the placebo group completed the
scheduled 24-month treatment (67). No differences were
observed between the two groups either in endoscopic
findings or the rate of clinical relapse. The so-called
Rutgeerts scores were after three months of treatment
0.6±0.8 in the synbiotic-treated group and 0.8±1 in the
placebo group (NS); (ii) general intensive care patients:
two large studies have been performed in a general
intensive care population; one with Synbiotic 2000 and
one with Synbiotic 2000 Forte. Synbiotic 2000 (40 billion
LAB) was given to 162 patients and in the synbiotic
composition only with fibres to 168 patients. No differ-
ence was observed in mortality or in multi-organ dys-
function (68). In another study, 130 patients were sup-
plemented with Synbiotic 2000 Forte (2×400 billion LAB)
twice a day throughout the whole ICU stay and com-
pared to 129 patients supplemented with a cellulose-
-based placebo. No statistical difference was demon-
strated between the groups in the incidence of VAP (9
and 13 %, p=0.31). The rate of VAP per 1000 ventilator
days was 13 and 14.6 (p=0.73) and hospital mortality 27
and 33 % (p=0.32), respectively (69).
Final Remarks
Thousands of factors are important to maintain health
and to cure disease. This might explain why single drug
pharmacy fails both to prevent a disease and to cure it,
especially when chronic. Human innate immunity for a
proper function much depends on continuous access to
bacteria and plants. Using probiotics in combination with
plants and their active ingredients remains an attractive
approach for prevention and treatment of various acute
and chronic diseases. Ten-year-old studies in the United
States demonstrate an 83 % reduction in the rate of coro-
nary heart disease (70), a 91 % reduction in diabetes in
women (71), and a 71 % reduction in colon cancer in
men (72) in patients adhering to what is regarded as an
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Table 3. Isolated bacteria in patients undergoing liver trans-
plantation and treated with Synbiotic 2000 or fibres
Isolated bacteria Synbiotic-treated Fibre-treated
Enterococcus faecalis 1 11
Escherichia coli 0 3
Enterobacter cloacae 0 2
Pseudomonas aeruginosa 0 2
Staphylococcus aureus 0 1
Total 1 18
'healthy lifestyle': no use of tobacco, moderate use of
alcohol, regular physical exercise, and eating a diet low
in animal fat, low in refined carbohydrates, and rich in
fresh fruits and vegetables (if raw also rich in lactic acid
bacteria) and fish, a diet often referred to as Mediterran-
ean diet.
Crohn's disease, as an example, has, despite vigo-
rous attempts over the years, remained most resistant to
therapy, pharmaceutical as well as probiotic treatments –
see recent review (73). Solid observations suggest that
several Th1-mediated autoimmune diseases, such as
multiple sclerosis, type 1 diabetes, rheumatoid arthritis
and Crohn's disease are associated with low vitamin D
status, and a recent study demonstrates strong molecu-
lar links between vitamin D deficiency and the genetics
of Crohn's disease (74). Crohn's disease is also strongly
associated with lack of minerals, especially calcium and
magnesium. Hypomagnesaemia is known to be strongly
associated with increased systemic inflammation, mani-
festing in leukocyte and macrophage activation and in-
creased production of inflammatory cytokines and acute
phase proteins. A recent study has demonstrated a much
deranged microbiota in experimental animals with in-
duced hypomagnesaemia (75). It is certainly too much
to request that pre-, pro-, or synbiotics make a difference
in such conditions unless the underlying defects in meta-
bolism and immune functions are corrected.
Inflammation is 'the mother of disease' and much
associated with the food we eat (76,77). As pointed out
above, numerous factors contribute to the deranged in-
nate immune system and the sustained exaggerated in-
flammation. Numerous changes are also required to
permanently control the hyper-inflammation and subse-
quent disease. Supply of pre-, pro-, and synbiotics is a
strong tool for such corrections of immune functions and
resistance to disease. However, in most instances also
other measures are necessary, including reduction in the
intake of pro-inflammatory molecules (2,78), and also
substantial intake of anti-inflammatory food ingredients
such as turmeric/curcumin (79,80).
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